Dysfunctional Mitochondrial Dynamics in the Pathophysiology of Neurodegenerative Diseases

Florian Haun1–4, Tomohiro Nakamura1 and Stuart A. Lipton1

1Del E. Webb Center for Neuroscience, Aging, and Stem Cell Research, Sanford-Burnham Medical Research Institute, La Jolla, CA. 2Institute of Molecular Medicine and Cell Research; 3Spemann Graduate School of Biology and Medicine; 4Faculty of Biology, Albert Ludwigs University Freiburg, Freiburg, Germany. Corresponding author email: slipton@sanfordburnham.org

Abstract: Mitochondrial dysfunction occurs in neurodegenerative diseases, however molecular mechanisms underlying this process remain elusive. Emerging evidence suggests that nitrosative stress, mediated by reactive nitrogen species (RNS), may play a role in mitochondrial pathology. Here, we review findings that highlight the abnormal mitochondrial morphology observed in many neurodegenerative disorders including Alzheimer’s, Parkinson’s, and Huntington’s diseases. One mechanism whereby RNS can affect mitochondrial function and thus neuronal survival occurs via protein S-nitrosylation, representing chemical reaction of a nitric oxide (NO) group with a critical cysteine thiol. In this review, we focus on the signaling pathway whereby S-nitrosylation of the mitochondrial fission protein Drp1 (dynamin-related protein 1; forming S-nitrosothiol (SNO)-Drp1) precipitates excessive mitochondrial fission or fragmentation and consequent bioenergetic compromise. Subsequently, the formation of SNO-Drp1 leads to synaptic damage and neuronal death. Thus, intervention in the SNO-Drp1 pathway may provide therapeutic benefit in neurodegenerative diseases.

Keywords: S-nitrosothiol, neurodegeneration, dendritic spine loss, GTPase, reactive nitrogen species, mitochondrial dysfunction

Journal of Cell Death 2013:6 27–35
doi: 10.4137/JCD.S10847

This article is available from http://www.la-press.com.

© the author(s), publisher and licensee Libertas Academica Ltd.

This is an open access article published under the Creative Commons CC-BY-NC 3.0 license.
Introduction

Mitochondria are dynamic organelles capable of establishing interconnected networks. Dynamic morphological changes are mediated by continual, highly-regulated fusion and fission events, collectively termed mitochondrial dynamics. For example, the evolutionarily conserved GTPase, dynamin related protein1 (Drp1), is known to participate in the process of mitochondrial fission. When mitochondria undergo fission, cytosolic Drp1 translocates to the outer mitochondrial membrane, oligomerizes around mitochondrial tubules, and in conjunction with Fis1 promotes division or fission. The fusion machinery consists mainly of three additional large dynamin-like GTPases: both mitofusin1/2 (Mfn1/2) and optic atrophy protein 1 (Opa1). The strict regulation of the equilibrium between fusion and fission events governs mitochondrial dynamics in a healthy cell and is crucial to maintaining mitochondrial function affecting energy supply, response to apoptotic stimuli, mitochondrial inheritance via admixture of mitochondrial-DNA (mtDNA), and translocation of mitochondria to regions of high-energy demand.

Although mitochondrial dynamics are crucial in all cell types, neurons are thought to be especially dependent on a dynamic mitochondrial network. With their often long processes, neurons require proper distribution of mitochondria across long distances to satisfy the energy requirements of electrical excitability and synaptic transmission (Fig. 1). To this end, healthy neurons precisely control mitochondrial dynamics in order to efficiently transport mitochondria to distal locations, including dendrites, axons, and synapses. Thus, mitochondrial function is essential to many cell types.

Figure 1. Proposed model of excessive mitochondrial fission contributing to neurodegenerative disorders. Balanced mitochondrial dynamics (mitochondrial fission and fusion events) facilitate proper distribution of neuronal mitochondria within neuronal dendrites and into synaptic termini. In addition, the precise control of mitochondrial fission and fusion events in axons is needed to support normal neuronal function (e.g., via production of ATP and buffering of Ca^{2+}). Malfunction of the fission or fusion machinery can result in excessive mitochondrial fragmentation under neurodegenerative conditions, leading to bioenergetic failure and subsequent synaptic damage.
neuronal functions, including energy production, Ca\(^{2+}\) buffering, axonal and dendritic transport, and release and re-uptake of neurotransmitter.\(^5\,^5\)

In order to maintain a proper distribution of functional mitochondria, both fusion and fission must occur in homeostatic balance. Basal activity of the fission machinery is required to divide the mitochondrial network into transportable units which can then be efficiently distributed to synapses.\(^3\) Fusion is necessary to maintain bioenergetic integrity of mitochondria.\(^5\)

If the balance of fission and fusion becomes biased (e.g., with increased fission or impaired fusion) excessive mitochondrial fragmentation is observed, resulting in impaired mitochondrial translocation and energy production at synaptic sites (Fig. 1).\(^1\,^3\)

The synaptic dysfunction thus induced is typically followed by dendritic and axonal degeneration, leading to neurodegeneration. Indeed, excessive mitochondrial fragmentation with damaged cristae and resulting impaired bioenergetics are often associated with many neurological conditions, including stroke, Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD), as well as several metabolic diseases.\(^5\,^8\)

Pathological disturbance of mitochondrial dynamics can result from either: 1) rare genetic mutations, such as those described for Mfn1/2, Opal1 and Drp1, which underlie Charcot-Marie-Tooth neuropathy type 2A (CMT2A),\(^9\) autosomal dominant optic atrophy (ADOA),\(^6\,^10\) and a rare disorder of brain development,\(^11\) respectively; or 2) altered posttranslational modifications (PTMs) of the proteins encoded by these genes that are responsible for the fission/fusion machinery.\(^5\,^12\)

In this review, we discuss recent findings concerning aberrant PTMs which regulate the mitochondrial fusion and fission machinery and thus contribute to the pathophysiology of neurodegenerative diseases. In particular, we focus on involvement of nitrosative stress-induced Drp1 activation, which results in excessive mitochondrial fragmentation, impaired bioenergetics, and consequent synaptic damage in neurodegenerative disorders.\(^2\,^12\,^13\)

**Mitochondrial Dynamics in Neurodegeneration**

As mentioned above, tight regulation of the mitochondrial fission/fusion machinery is essential for maintaining healthy neuronal physiology. However, dysfunctional mitochondrial dynamics caused by impaired mitochondrial fission or fusion is a hallmark of many neurodegenerative diseases and contributes to their pathophysiology.

**Impaired mitochondrial fission and fusion in neurodegenerative diseases**

Mitochondrial fusion is the process by which the inner and outer mitochondrial membranes are separately fused by Opal1 and Mfn1/2, respectively.\(^3\,^6\) Mutations in these genes result in rare neurological conditions. For example, loss of function mutations in the Mfn2 gene disrupts mitochondrial fusion, resulting in distal muscle weakness and sensory loss in CMT2A.\(^14\)

To date, more than 40 mutations have been identified, most of which are located in the conserved GTPase domain of Mfn2.\(^9\,^15\) In mouse models, deletion in the mouse Mfn2 gene causes severe mtDNA loss and the accumulation of mtDNA mutations.\(^16\)

In addition, Mfn2 deficiency results in decreased axonal transport of mitochondria, causing a lack of functional mitochondria at pre- and postsynaptic sites.\(^17\)

Collectively, these findings suggest that Mfn2 mutations in CMT2A patients may trigger defects both in mtDNA integrity and mitochondrial transport, contributing to disease pathogenesis.

Another neurologic disorder caused by disruption in the fusion machinery is ADOA,\(^6\) representing an hereditary optic nerve atrophy characterized by degeneration of retinal ganglion cells and progressive loss of vision. Mutations in the Opal1 gene, and to a lesser extent in Opal3, underlie ADOA.\(^10\) Similar to Mfn2 mutations, over 100 reported mutations in Opal1 target predominantly the GTPase domain.\(^18\)

Opal1 is located at the inner mitochondrial membrane, regulating fusion and modeling of the cristae structures. Interestingly, most Opal1 mutations identified in the GTPase domain cause ADOA via a dominant-negative effect. Furthermore, heterozygous Opal1 knockout mice manifest severe degeneration of the optic nerves, similar to human ADOA.\(^19\)

Due to decreased mitochondrial fusion activity, disruption of Opal1 GTPase activity results in increased mitochondrial fragmentation, possibly making the retinal ganglion cells more susceptible to apoptosis.\(^20\,^21\)

However, further analyses are needed to determine whether mitochondrially-mediated apoptotic pathways are implicated in the pathogenesis of ADOA.
PTM regulation of Drp1 activity and mitochondrial dynamics

Recently, we discovered that Drp1 is a target of S-nitrosylation, a covalent modification of free thiol by a nitric oxide (NO) group, forming an S-nitrosothiol (R-SNO). Specifically, we found that S-nitrosylation of Cys644 within the GED domain of Drp1 enhances its GTPase activity and results in excessive mitochondrial fragmentation.

S-Nitrosylation of Drp1 and its involvement in neurologic disorders will be discussed in detail in later sections.

In addition to S-nitrosylation, Drp1 undergoes multiple other PTMs including phosphorylation, SUMOylation, and ubiquitination. Among these Drp1 PTMs, the effects of phosphorylation are perhaps best studied. For example, it is known that phosphorylation of Drp1 at Ser616 by CDK1/cyclin B can increase its GTPase activity. Consequently, Cdk1-dependent phosphorylation of Drp1 results in an increase in mitochondrial fragmentation. S-Nitrosylation of Drp1 and its involvement in neurologic disorders will be discussed in detail in later sections.

In addition to S-nitrosylation, Drp1 undergoes multiple other PTMs including phosphorylation, SUMOylation, and ubiquitination. Among these Drp1 PTMs, the effects of phosphorylation are perhaps best studied. For example, it is known that phosphorylation of Drp1 at Ser616 by CDK1/cyclin B can increase its GTPase activity. Consequently, Cdk1-dependent phosphorylation of Drp1 results in an increase in mitochondrial fragmentation. In addition, cyclic AMP-dependent protein kinase (PKA) phosphorylates Drp1 at Ser637 and decreases Drp1 activity by inhibiting molecular interactions. PKA-mediated phosphorylation can be counteracted by calcineurin-induced dephosphorylation of Ser637, resulting in translocation of Drp1 to the mitochondrial membrane to form a complex with Fis1, resulting in increased}

...
mitochondrial fission. Therefore, additional studies are needed to clarify the basis for the differential effects of PKA and CamKIIα.

Drp1 activity is also affected by SUMOylation, which occurs within the insert B domain (Fig. 2). The attachment of a small ubiquitin-related modifier 1 (SUMO1) to the lysine residues of Drp1 stabilizes the protein and thus increases mitochondrial fragmentation. Several proteins, including SUMO1, Ubc9, and MAPL, have been shown to mediate Drp1 SUMOylation. This stabilizing modification can be reversed by sentrin/SUMO-specific protease (SENP5). In addition to SUMOylation, the lysine residues of Drp1 can be ubiquitinated. Parkin and mitochondrial E3 ligase protein MARCH5 can ubiquitinate Drp1 on lysine residues located in the middle domain. Initial studies reported that MARCH5 activity promoted mitochondrial fusion and elongation, suggesting that MARCH-dependent ubiquitination of Drp1 inhibited its activity. However, a subsequent report by Karbowski et al. found that MARCH5 activity is required for mitochondrial fission. Although one could speculate that different expression levels of MARCH5 might cause these opposite effects, the physiological action of MARCH5-mediated ubiquitination on Drp1 certainly warrants further investigation.

Additionally, parkin-mediated ubiquitination of Drp1 results in its proteasomal degradation. Parkin is a RING-type ubiquitin E3 ligase expressed in many human tissues, including brain, heart, testis, and skeletal muscle. In the human brain, parkin is primarily expressed in neurons in various regions, including the substantia nigra in the midbrain as well as in the CA1/3 region of the hippocampus. Since mutations in the parkin gene cause a familial form of PD, it is tempting to speculate that abnormal regulation of the parkin-Drp1 pathway, which would lead to impaired mitochondrial dynamics, might contribute to the pathogenesis of PD.

S-Nitrosylation, Enhanced Mitochondrial Fission, and Neurodegeneration
NO/reactive nitrogen species and neurodegeneration
Over the past twenty years, numerous reports identified NO as a crucial protein-modifying molecule in cell biology, affecting many target proteins through S-nitrosylation. Depending on the target protein, the effects of S-nitrosylation can be quite diverse. NO is typically generated from NO synthase (NOS) during the conversion of L-arginine to L-citrulline. NO production can be controlled by transcriptional activation of inducible NOS (iNOS), or by Ca²⁺/calmodulin dependent activation of neuronal or endothelial NOS (nNOS or eNOS). A well-characterized pathway for NO production in the nervous system occurs via activation of the N-methyl-D-aspartate-type glutamate receptor (NMDAR). NMDAR stimulation results in the influx of Ca²⁺, which, together with calmodulin, stimulates nNOS to generate NO. Prior to the discovery of S-nitrosylation, initial studies of NO signaling concentrated on its physiological and neuroprotective functions mediated by activation of soluble guanylate cyclase (sGC) and subsequent production of cGMP. Subsequently, accumulating evidence has suggested that in a variety of diseases, including AD, HD and PD, nitrosative and oxidative stress appear to trigger aberrant S-nitrosylation events that contribute to neurodegeneration. For example, pathological S-nitrosylation reactions include NO-mediated modifications to parkin and protein disulfide isomerase (PDI). Additionally, we recently discovered that aberrant S-nitrosylation of Drp1 hyperactivates its mitochondrial fission activity. In this case, NO triggers excessive mitochondrial fission accompanied by increased autophagy (mitophagy) and decreased ATP production, which contributes to synaptic damage conditions such as AD. In addition to SNO signaling pathways, NO can react with superoxide anion, generated from mitochondrial as well as non-mitochondrial sources (e.g., NADPH oxidase), to form peroxynitrite (ONOO⁻). Peroxynitrite can result in lipid peroxidation and tyrosine nitration, another NO-mediated PTM that causes pathological alteration in target protein activity, as reviewed elsewhere.
Figure 3. NO signaling pathways in the nervous system. Left: Under physiological conditions, basal levels of NO from nNOS, stimulated by normal synaptic activity of N-methyl-D-aspartate-type glutamate receptors (NMDARs), provide neuroprotection via sGC/cGMP pathways as well as S-nitrosylation of NMDARs and caspases. Right: Under pathophysiological conditions, overactivation of NMDARs, especially extrasynaptic NMDARs, results in increased production of NO. Additionally, iNOS can generate toxic amounts of NO. Excessive NO can lead to S-nitrosylation of Drp1 (forming SNO-Drp1), which contributes to neuronal synaptic injury via excessive mitochondrial fission and bioenergetic impairment. Additionally, S-nitrosylation of PDI, Parkin, XIAP, and GAPDH can contribute to neurodegenerative disorders.

by intracellular neurofibrillary tangles, composed of hyperphosphorylated tau, and extracellular amyloid plaques, comprised of amyloid-β (Aβ) peptide. Soluble oligomers of Aβ arise from the proteolytic cleavage of amyloid precursor protein (APP) and are thought to contribute to the pathogenesis of AD. Additional evidence accumulated over the past decade has suggested that altered mitochondrial function associated with dysregulated mitochondrial dynamics is another key feature of AD.\textsuperscript{13,47,51,52}

Recently, the neurotoxic Aβ oligomers were reported to cause excessive mitochondrial fragmentation in cell-based models of AD.\textsuperscript{12} Specifically, Aβ oligomer-induced generation of NO resulted in S-nitrosylation of Drp1 (forming SNO-Drp1), which was found to hyperactivate its GTPase activity and induce excessive mitochondrial fragmentation. The resulting disruption of mitochondrial bioenergetics caused a drop in ATP levels and consequent synaptic damage. Drp1 as shown to be S-nitrosylated at cysteine residue 644, located in the GED domain. Importantly, mutation of Drp1 Cys644 to an alanine abrogated Aβ/NO-induced mitochondrial fission, consistent with the notion that the mitochondrial fragmentation was at least in part mediated by formation of SNO-Drp1. In AD, the only neuropathological correlation with cognitive decline is the degree of synaptic loss. Interestingly, Drp1-C644A (representing a nitrosylation-resistant mutant) prevented Aβ-induced synaptic damage, suggesting that S-nitrosylation of Drp1 at Cys644 contributes to Aβ toxicity in AD. Moreover, the non-nitrosylatable Drp1 mutant
prevented nitrosative stress-induced neuronal cell death, lending support to the role of SNO-Drp1 in NO-mediated neuronal damage.

Although this pathway of aberrant SNO-Drp1 formation was initially discovered in human AD brains and animal models of AD, many other neurodegenerative conditions, including PD and HD, are characterized by increased oxidative and nitrosative stress.53

Consistent with this notion, SNO-Drp1 is present at very early stages in the substantia nigra of PD animal models induced by pesticide exposure. Additionally, SNO-Drp1 appears to contribute to mutant huntingtin (mtHtt)-induced neurotoxicity in cell-based and animal models of HD.54 HD is an adult-onset, genetic neurodegenerative disorder caused by an aberrant expansion of a trinucleotide CAG repeat in the htt gene. The CAG expansion, translated into an expanded polyglutamine (polyQ) repeat in the mtHtt protein, accelerates toxic misfolding of mtHtt, leading to interference with several critical molecular cascades in the cell, and resultant degeneration of synapses and neurons in the affected brain area (i.e., the striatum and cortex).

Similar to the effects of Aβ oligomers on SNO-Drp1, expression of mtHtt significantly increased NO production and subsequently up-regulated the levels of SNO-Drp1 in primary cultures of cortical neurons. Further along these lines, SNO-Drp1 formation was considerably elevated in the striatum of a transgenic mouse model of HD as well as in human postmortem brains from HD patients.54 In a cell culture model of HD, transfection of a non-nitrosylatable mutant form of Drp1 abrogated the neurotoxic effects of mtHtt on mitochondrial fragmentation and dendritic spine damage, suggesting that SNO-Drp1 is a key mediator of this form of mtHtt toxicity. Taken together, these findings imply that S-nitrosylation of Drp1 may occur in other neurodegenerative conditions, contributing to aberrant mitochondrial dynamics and downstream neuronal damage.

Conclusions and Future Directions
In the present study, we review how PTMs of Drp1, particularly S-nitrosylation, may contribute to excessive mitochondrial fragmentation in neurodegenerative diseases. These findings strengthen the hypothesis that aberrant protein S-nitrosylation may play a key role in the contribution of mitochondrial pathology to many neurodegenerative diseases. Importantly, the demonstration that preventing formation of SNO-Drp1 can ameliorate Aβ- or mtHtt-induced synaptic damage in models of AD and HD, respectively, suggests a new therapeutic approach based on developing drugs to affect disease-related protein S-nitrosylation. Additionally, we anticipate that additional examples of aberrant S-nitrosylation as well as other PTM events will be discovered which influence mitochondrial dynamics and function in a number of other neurodegenerative disorders.

Another important area for future research into the effect of SNO-Drp1 concerns the discovery of endogenous compounds, including nitrosylase and denitrosylase enzymes which regulate its formation and destruction. Related to this question, we recently discovered that SNO-Cdk5 can act as an endogenous nitrosylase, enhancing SNO-Drp1 levels via transnitrosylation of Drp1 (i.e., SNO-Cdk5 donates an NO group to Drp1 to form SNO-Drp1).55 Further efforts to identify additional molecular controls of aberrant S-nitrosylation of Drp1 will be critical in determining not only the downstream signaling consequences but also for formulating new therapies for several neurological disorders.

Author Contributions
Wrote the first draft of the manuscript: FH and TN. Agree with manuscript results and conclusions: FH, TN, and SAL. Jointly developed the structure and arguments for the paper: FH, TN, and SAL. Made critical revisions and approved final version: FH, TN, and SAL. All authors reviewed and approved of the final manuscript.

Funding
This work was supported in part by grants from the Alzheimer Association (to TN), the Michael J. Fox Foundation (to TN and SAL), and the NIH (P01 ES016738, P01 HD29587, and P30 NS076411) to SAL.

Competing Interests
Author(s) disclose no potential conflicts of interest.

Disclosures and Ethics
As a requirement of publication the authors have provided signed confirmation of their compliance with
ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research participants (if applicable), and that permission has been obtained for reproduction of any copyrighted material. This article was subject to blind, independent, expert peer review. The reviewers reported no competing interests. Provenance: the authors were invited to submit this paper.

References

1. Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. *Science*. 2012;337(6098):1062–1065.
2. Hoppins U, Nunnari J. The molecular mechanism of mitochondrial fusion. *Biochim Biophys Acta*. 2009;1793(1):20–26.
3. Westermann B. Mitochondrial fusion and fission in cell life and death. *Nat Rev Mol Cell Biol*. 2010;11(12):872–884.
4. Sheng ZH, Cai Q. Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. *Nat Rev Neurosci*. 2012;13:77–93.
5. Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. *Nat Rev Neurosci*. 2008;9(7):505–518.
6. Oliphant A, Guilhou E, Delettre C, et al. Mitochondrial dynamics and disease. *OPA1*. *Biochim Biophys Acta*. 2006;1763(5–6):500–509.
7. Su B, Wang X, Zheng L, Perry G, Smith M, Zhu X. Abnormal mitochondrial dynamics and neurodegenerative diseases. *Biochim Biophys Acta*. 2010;1802(1):135–142.
8. Shirendeb U, Reddy AP, Manzczak M, et al. Abnormal mitochondrial dynamics, mitochondrial loss, and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage. *Hum Mol Genet*. 2011;20(7):1438–1445.
9. Zuchner S, Mersiyanova IV, Muglia M, et al. Mutations in the mitochondrial OPA1 fusion gene in Charcot-Marie-Tooth disease type 2A. *Nat Genet*. 2004;36(5):449–451.
10. Alexander C, Votrubka M, Pesch UE, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. *Nat Genet*. 2000;26(2):211–215.
11. Waterham HR, Koster J, van Roermund CW, Moozer PA, Wanders RJ, Leonard JV. A lethal defect of mitochondrial and peroxisomal fission. *N Engl J Med*. 2007;356(17):1736–1741.
12. Cho D-H, Nakamura T, Fang J, et al. S-Nitrosylation of Drp1 Mediates b-Amyloid-Related Mitochondrial Fission and Neuronal Injury. *Science*. 2009;324(5923):102–105.
13. Wang X, Su B, Lee HG, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. *J Neurosci*. 2009;29(28):9090–9013.
14. Reilly MM, Murphy SM, Lauré M. Charcot-Marie-Tooth disease. *J Peripher Nerv Syst*. 2011;16(1):1–14.
15. Lawson VH, Graham BV, Flanagan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. *Neurology*. 2005;65(2):197–204.
16. Chen H, Vermulst M, Wang YE, et al. Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. *Cell*. 2010;141(2):280–289.
17. Misko A, Jiang S, Wegrzynska I, Milbrandt J, Baloh RH. Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. *J Neurosci*. 2010;30(12):4232–4240.
18. Ferre M, Amati-Bonneau P, Tournem Y, Malthiéry Y, Reymier P. OPA1: an online database for OPA1 mutations. *Hum Mutat*. 2005;25(5):423–428.
19. Davies VJ, Hollins AJ, Piechota MJ, et al. OPA1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. *Hum Mol Genet*. 2007;16(11):307–318.
20. Lee Y, Yeong SY, Karbowiak M, L SC, Youle RJ. Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. *Mol Biol Cell*. 2004;15(11):5001–5011.
21. Olichon A, Baricault L, Gas N, et al. Loss of OPA1 perturbs the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. *J Biol Chem*. 2003;278(10):7743–7746.
22. Cho DH, Nakamura T, Lippton SA. Mitochondrial dynamics in cell death and neurodegeneration. *Cell Mol Life Sci*. 2010;67(20):3435–3447.
23. Ford MG, Jenni S, Nunnari J. The crystal structure of dynamin. *Nature*. 2011;477(7366):561–566.
24. Faeder K, Posor Y, Gao S, et al. Crystal structure of nucleotide-free dynamin. *Nature*. 2011;477(7366):556–560.
25. Chang CR, Manlando CM, Aarnout D, et al. A lethal de novo mutation in the middle domain of the dynamin-related GTPase Drp1 impairs higher order assembly and mitochondrial division. *J Biol Chem*. 2010;285(42):32944–32953.
26. Han XJ, Lu YE, Li SA, et al. CaM kinase I alpha-induced phosphorylation of Drp1 regulates mitochondrial morphology. *J Cell Biol*. 2008;182(3):573–585.
27. Figueyroa-Cermeño C, Iniguez-Lluhi JA, Stadler J, et al. SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle. *FASEB J*. 2009;23(11):3917–3927.
28. Zunino R, Schauss A, Rippstein P, Andrade-Navarro M, McBride HM. The SUMO protease SENP5 is required to maintain mitochondrial morphology and function. *J Cell Sci*. 2007;120(7):1178–1188.
29. Zappia M, Braschi E, Xu L, McBride HM. Translocation of SENP5 from the nucleoli to the mitochondria modulates DRP1-dependent fission during mitosis. *J Biol Chem*. 2009;284(26):17783–17795.
30. Nakamura N, Kimura Y, Tokuda M, Honda S, Hirose S. MARCH-V is a novel mitofusin 2- and Drp1-binding protein able to change mitochondrial morphology. *EMBO Rep*. 2006;7(10):1099–1022.
31. Parkinson’s disease, OPA1. *Science*. 2006;25(15):3619–3626.
32. Karbowiak M, Neutzen A, Youle RJ. The mitochondrial OPA3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division. *J Cell Biol*. 2007;178(1):71–84.
33. Wang H, Song P, Du L, et al. Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication of dysregulated mitochondrial dynamics in Parkinson disease. *J Biol Chem*. 2011;286(13):11649–11658.
34. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature*. 1998;392(6676):605–608.
35. Solano SM, Miller DW, Augood SJ, et al. Expression of alpha-synuclein, parkin, and ubiquitin carboxyl-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson’s disease. *Ann Neurol*. 2000;47(2):201–210.
36. Nakamura T, Lippton SA. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. *Cell Death Differ*. 2011;18(9):1478–1476.
Dysfunctional mitochondrial dynamics in the pathophysiology of neurodegenerative diseases

41. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 2005;6(2):150–166.

42. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 1991;351(6329):714–718.

43. Brennan JE, Chao DS, Gee SH, et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell. 1996;84(5):757–767.

44. Chung KK, Thomas B, Li X, et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science. 2004;304(5675):1328–1331.

45. Uehara T, Nakamura T, Yao D, et al. S-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature. 2006;441(7092):513–517.

46. Yao D, Gu Z, Nakamura T, et al. Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A. 2004;101(29):10810–10814.

47. Barsoum MJ, Yuan H, Gerencser AA, et al. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J. 2006;25(16):3900–3911.

48. Brennan AM, Suh SW, Won SJ, et al. NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation. Nat Neurosci. 2009;12(7):857–863.

49. Lipton SA, Choi YB, Pan ZH, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and realted nitroso-compounds. Nature. 1993;364(6438):626–632.

50. Radi R, Peluffo G, Alvarez MN, Naviliat M, Cayota A. Unraveling peroxynitrite formation in biological systems. Free Radic Biol Med. 2001;30(5):463–488.

51. Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage. Hum Mol Genet. 2011;20(13):2495–2509.

52. Wang X, Su B, Siedlak SL, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins Proc Natl Acad Sci U S A. 2008;105(49):19318–19323.

53. Okamoto S, Pouladi MA, Talantova M, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med. 2009;15(12):1407–1413.

54. Haun F, Nakamura T, Shiu AD, et al. S-Nitrosylation of Drp1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington’s disease. Antioxid Redox Signal. 2013 June 20, [Epub ahead of print].

55. Qu J, Nakamura T, Cao G, et al. S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by beta-amyloid peptide. Proc Natl Acad Sci U S A. 2011;108(34):14330–14335.